• Limula has appointed Dr. Jonathan Esensten to its Strategic Advisory Board as it advances its automated Cell and Gene Therapy (CGT) manufacturing solutions.
  • The appointment follows the launch of LimONE, Limula’s integrated bioreactor and centrifuge platform, aimed at streamlining CGT production.

Life science tools company specializing in automated Cell and Gene Therapy (CGT) manufacturing solutions, Limula has appointed Dr. Jonathan Esensten to its Strategic Advisory Board.

The appointment follows the company’s recent unveiling of LimONE, its flagship product designed to integrate all cell therapy manufacturing steps into a single platform using a proprietary bioreactor and centrifuge technology.

Dr. Esensten, a physician-scientist, is the director of the Advanced Biotherapy Center at Sheba Medical Center, Israel. He has a background in cellular immunology, clinical pathology, and transfusion medicine, having trained at the University of California, San Francisco (UCSF), where he later served as a faculty member in the Department of Laboratory Medicine from 2017 to 2023. Throughout his career, he has led multiple cell therapy projects in collaboration with academic institutions, large pharmaceutical companies, and biotechnology firms.

Expressing his enthusiasm about joining Limula, Dr. Esensten stated,

“I am delighted to join the Limula Strategic Advisory Board at this exciting stage of the company’s development. I look forward to working with their Head of Solutions, Dr. Caroline Boudousquié, and the entire team to maximize the impact of their promising technology.”

Limula CEO Dr. Luc Henry highlighted the significance of Dr. Esensten’s expertise in shaping the company’s future direction.

“Jonathan brings deep scientific expertise that will be instrumental in refining experimental strategies. His guidance will help strengthen our approach in translating technology differentiation into better cell products for our customers and support the further development of our products,” he said.

He further emphasized that Dr. Esensten’s external perspective and industry connections will help align the company’s scientific activities with best practices and future innovations while enhancing collaboration opportunities.

In addition to this appointment, Limula has recently expanded its team, bringing in professionals with expertise in cell therapy, life science tools, product development, industrialization, and manufacturing. The company aims to strengthen its position in the CGT sector by advancing its technology and fostering industry partnerships.

Edited by Harshajit Sarmah